Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Pipeline & R&D

Corbus enrols first patient in pivotal-intent TEMPO-1 head-and-neck trial for Nectin-4 ADC

The US biotech's updated investor deck shows its lead antibody-drug conjugate moving into a late-stage study, with about $115M in cash and investments backing it and an obesity asset.

16 Nov 2026 · Corbus Pharmaceuticals Holdings, Inc. CRBP · Company news

Corbus Pharmaceuticals has begun treating patients in TEMPO-1, the study intended to support registration of its Nectin-4-directed antibody-drug conjugate, sutantatug envedotin (SUTA-E), in oropharyngeal squamous cell carcinoma (OPSCC). The company says dosing began in September 2026. The news comes from a refreshed corporate presentation with figures dated 30 September 2026.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Corbus Pharmaceuticals Holdings, Inc. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Pipeline & R&DAll →